Literature DB >> 20138481

High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria.

Gwan-Han Shen1, Bo-Da Wu, Shiau-Ting Hu, Chen-Fu Lin, Kun-Ming Wu, Jiann-Hwa Chen.   

Abstract

The aim of this study was to determine whether clofazimine, dapsone and cycloserine may be suitable antimicrobial agents for the treatment of infections due to rapidly growing mycobacteria (RGM). The antimicrobial activity of the three drugs against 117 Mycobacterium abscessus isolates, 48 Mycobacterium fortuitum isolates and 20 Mycobacterium chelonae isolates was evaluated based on their broth microdilution minimal inhibitory concentrations (MICs) against the isolates. Clofazimine was highly efficacious against these RGM. The vast majority of M. abscessus, M. fortuitum and M. chelonae isolates (99.1%, 91.7% and 100%, respectively) had clofazimine MICs of <or=1mg/L. MIC(50) values (MIC for 50% of the organisms) of clofazimine against the isolates ranged from 0.25mg/L to 0.5mg/L and MIC(90) values (MIC for 90% of the organisms) ranged from 0.5mg/L to 1.0mg/L. Cycloserine and dapsone had little or no activity against the isolates. The effects of combined application of clofazimine and amikacin on 40 M. abscessus isolates, 48 M. fortuitum isolates and 20 M. chelonae isolates were evaluated. Addition of 0.25x MIC of amikacin for the isolates to clofazimine reduced clofazimine MICs in all of the M. abscessus and M. chelonae isolates and in 48% of the M. fortuitum isolates tested. Clofazimine, either alone or combined with amikacin, may serve as a promising drug for the treatment of RGM infections. (c) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138481     DOI: 10.1016/j.ijantimicag.2009.12.008

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  33 in total

Review 1.  Activity of Dapsone versus Community and Hospital Pathogens from the CANWARD Study.

Authors:  George G Zhanel; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2016-03-01

2.  Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 3.  Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Gail L Woods
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

4.  Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.

Authors:  Bumhee Yang; Byung Woo Jhun; Seong Mi Moon; Hyun Lee; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Su-Young Kim; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

5.  Activities of Dual Combinations of Antibiotics Against Multidrug-Resistant Nontuberculous Mycobacteria Recovered from Patients with Cystic Fibrosis.

Authors:  Matthew Schwartz; Stefanie Fisher; Elizabeth Story-Roller; Gyanu Lamichhane; Nicole Parrish
Journal:  Microb Drug Resist       Date:  2018-01-25       Impact factor: 3.431

6.  In Vitro Susceptibility of Nocardia farcinica to the Antimycobacterial Drug Clofazimine.

Authors:  Ka Lip Chew; Sophie Octavia; Siang Fei Yeoh; Jeanette W P Teo
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

7.  Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Hyun Lee; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

8.  In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.

Authors:  Jakko van Ingen; Sarah E Totten; Niels K Helstrom; Leonid B Heifets; Martin J Boeree; Charles L Daley
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

9.  The Challenge of Pulmonary Nontuberculous Mycobacterial Infection.

Authors:  Shannon Novosad; Emily Henkle; Kevin L Winthrop
Journal:  Curr Pulmonol Rep       Date:  2015-07-12

10.  In Vitro Activity of Clofazimine against Nontuberculous Mycobacteria Isolated in Beijing, China.

Authors:  Jingjing Luo; Xia Yu; Guanglu Jiang; Yuhong Fu; Fengmin Huo; Yifeng Ma; Fen Wang; Yuanyuan Shang; Qian Liang; Yi Xue; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.